Imaging-concordant benign mriguided vacuum-assisted breast biopsy may not warrant MRI Follow-Up

Monica L. Huang, Megan Speer, Basak E. Dogan, Gaiane M. Rauch, Rosalind P. Candelaria, Beatriz E. Adrada, Kenneth R. Hess, Wei T. Yang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

OBJECTIVE. The follow-up of breast lesions with imaging-concordant benign histopathology results on MRI-guided vacuum-assisted biopsy (VAB) is not currently standardized. We determined the false omission rate of breast MRI-guided VAB with benign histopathology (negative results) to assess whether breast MRI follow-up is needed. MATERIALS AND METHODS. The medical records of patients who underwent 9-gauge breast MRI-guided VAB during 2007-2012 were reviewed retrospectively. Lesions with imaging-concordant benign histopathology results from MRI-guided VAB and surgery or 2 years or more of imaging follow-up were included. The false omission rate (1 - negative predictive value; [number of false-negative results / number of negative results]) of MRI-guided VAB was calculated. RESULTS. One hundred sixty-nine lesions were included, and 135 had only imaging follow- up (mammography follow-up: range, 17-107 months [median, 52 months]; MRI followup: range, 5-95 months [median, 35 months]). Of the 135 lesions with only imaging follow-up, 48 had mammography only (range, 26-86 months; median, 52 months), and 87 had mammography (range, 17-107 months; median, 52 months) and MRI (range, 5-95 months; median, 35 months). Thirty-four lesions had surgical correlation, and there were no cases of imaging-surgical discordance. Four malignancies were later diagnosed in the same breast in which MRIguided VAB had been performed. One (0.6%) malignancy was invasive ductal carcinoma at 1 cm from the MRI-guided VAB site; it was mammographically detected 24 months after MRIguided VAB. The other three malignancies developed 4 cm or more from the site of MRIguided VAB: one ductal carcinoma in situ (DCIS) detected on mammography 12 months after MRI-guided VAB, one DCIS detected on MRI 24 months after MRI-guided VAB, and one Paget disease lesion detected at physical examination 32 months after MRI-guided VAB. CONCLUSION. Breast MRI-guided VAB has a low false omission rate. MRI follow-up of lesions with concordant benign MRI-guided VAB histopathology results may not be warranted.

Original languageEnglish (US)
Pages (from-to)916-922
Number of pages7
JournalAmerican Journal of Roentgenology
Volume208
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Vacuum
Breast
Biopsy
Mammography
Carcinoma, Intraductal, Noninfiltrating
Neoplasms
Ductal Carcinoma
Physical Examination
Medical Records

Keywords

  • Benign
  • Breast
  • Imaging-concordant
  • MRI-guided
  • Vacuum-assisted breast biopsy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Imaging-concordant benign mriguided vacuum-assisted breast biopsy may not warrant MRI Follow-Up. / Huang, Monica L.; Speer, Megan; Dogan, Basak E.; Rauch, Gaiane M.; Candelaria, Rosalind P.; Adrada, Beatriz E.; Hess, Kenneth R.; Yang, Wei T.

In: American Journal of Roentgenology, Vol. 208, No. 4, 01.04.2017, p. 916-922.

Research output: Contribution to journalArticle

Huang, ML, Speer, M, Dogan, BE, Rauch, GM, Candelaria, RP, Adrada, BE, Hess, KR & Yang, WT 2017, 'Imaging-concordant benign mriguided vacuum-assisted breast biopsy may not warrant MRI Follow-Up', American Journal of Roentgenology, vol. 208, no. 4, pp. 916-922. https://doi.org/10.2214/AJR.16.16576
Huang, Monica L. ; Speer, Megan ; Dogan, Basak E. ; Rauch, Gaiane M. ; Candelaria, Rosalind P. ; Adrada, Beatriz E. ; Hess, Kenneth R. ; Yang, Wei T. / Imaging-concordant benign mriguided vacuum-assisted breast biopsy may not warrant MRI Follow-Up. In: American Journal of Roentgenology. 2017 ; Vol. 208, No. 4. pp. 916-922.
@article{71e6c5a2e61c4904b1c22b5c240413dd,
title = "Imaging-concordant benign mriguided vacuum-assisted breast biopsy may not warrant MRI Follow-Up",
abstract = "OBJECTIVE. The follow-up of breast lesions with imaging-concordant benign histopathology results on MRI-guided vacuum-assisted biopsy (VAB) is not currently standardized. We determined the false omission rate of breast MRI-guided VAB with benign histopathology (negative results) to assess whether breast MRI follow-up is needed. MATERIALS AND METHODS. The medical records of patients who underwent 9-gauge breast MRI-guided VAB during 2007-2012 were reviewed retrospectively. Lesions with imaging-concordant benign histopathology results from MRI-guided VAB and surgery or 2 years or more of imaging follow-up were included. The false omission rate (1 - negative predictive value; [number of false-negative results / number of negative results]) of MRI-guided VAB was calculated. RESULTS. One hundred sixty-nine lesions were included, and 135 had only imaging follow- up (mammography follow-up: range, 17-107 months [median, 52 months]; MRI followup: range, 5-95 months [median, 35 months]). Of the 135 lesions with only imaging follow-up, 48 had mammography only (range, 26-86 months; median, 52 months), and 87 had mammography (range, 17-107 months; median, 52 months) and MRI (range, 5-95 months; median, 35 months). Thirty-four lesions had surgical correlation, and there were no cases of imaging-surgical discordance. Four malignancies were later diagnosed in the same breast in which MRIguided VAB had been performed. One (0.6{\%}) malignancy was invasive ductal carcinoma at 1 cm from the MRI-guided VAB site; it was mammographically detected 24 months after MRIguided VAB. The other three malignancies developed 4 cm or more from the site of MRIguided VAB: one ductal carcinoma in situ (DCIS) detected on mammography 12 months after MRI-guided VAB, one DCIS detected on MRI 24 months after MRI-guided VAB, and one Paget disease lesion detected at physical examination 32 months after MRI-guided VAB. CONCLUSION. Breast MRI-guided VAB has a low false omission rate. MRI follow-up of lesions with concordant benign MRI-guided VAB histopathology results may not be warranted.",
keywords = "Benign, Breast, Imaging-concordant, MRI-guided, Vacuum-assisted breast biopsy",
author = "Huang, {Monica L.} and Megan Speer and Dogan, {Basak E.} and Rauch, {Gaiane M.} and Candelaria, {Rosalind P.} and Adrada, {Beatriz E.} and Hess, {Kenneth R.} and Yang, {Wei T.}",
year = "2017",
month = "4",
day = "1",
doi = "10.2214/AJR.16.16576",
language = "English (US)",
volume = "208",
pages = "916--922",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "4",

}

TY - JOUR

T1 - Imaging-concordant benign mriguided vacuum-assisted breast biopsy may not warrant MRI Follow-Up

AU - Huang, Monica L.

AU - Speer, Megan

AU - Dogan, Basak E.

AU - Rauch, Gaiane M.

AU - Candelaria, Rosalind P.

AU - Adrada, Beatriz E.

AU - Hess, Kenneth R.

AU - Yang, Wei T.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - OBJECTIVE. The follow-up of breast lesions with imaging-concordant benign histopathology results on MRI-guided vacuum-assisted biopsy (VAB) is not currently standardized. We determined the false omission rate of breast MRI-guided VAB with benign histopathology (negative results) to assess whether breast MRI follow-up is needed. MATERIALS AND METHODS. The medical records of patients who underwent 9-gauge breast MRI-guided VAB during 2007-2012 were reviewed retrospectively. Lesions with imaging-concordant benign histopathology results from MRI-guided VAB and surgery or 2 years or more of imaging follow-up were included. The false omission rate (1 - negative predictive value; [number of false-negative results / number of negative results]) of MRI-guided VAB was calculated. RESULTS. One hundred sixty-nine lesions were included, and 135 had only imaging follow- up (mammography follow-up: range, 17-107 months [median, 52 months]; MRI followup: range, 5-95 months [median, 35 months]). Of the 135 lesions with only imaging follow-up, 48 had mammography only (range, 26-86 months; median, 52 months), and 87 had mammography (range, 17-107 months; median, 52 months) and MRI (range, 5-95 months; median, 35 months). Thirty-four lesions had surgical correlation, and there were no cases of imaging-surgical discordance. Four malignancies were later diagnosed in the same breast in which MRIguided VAB had been performed. One (0.6%) malignancy was invasive ductal carcinoma at 1 cm from the MRI-guided VAB site; it was mammographically detected 24 months after MRIguided VAB. The other three malignancies developed 4 cm or more from the site of MRIguided VAB: one ductal carcinoma in situ (DCIS) detected on mammography 12 months after MRI-guided VAB, one DCIS detected on MRI 24 months after MRI-guided VAB, and one Paget disease lesion detected at physical examination 32 months after MRI-guided VAB. CONCLUSION. Breast MRI-guided VAB has a low false omission rate. MRI follow-up of lesions with concordant benign MRI-guided VAB histopathology results may not be warranted.

AB - OBJECTIVE. The follow-up of breast lesions with imaging-concordant benign histopathology results on MRI-guided vacuum-assisted biopsy (VAB) is not currently standardized. We determined the false omission rate of breast MRI-guided VAB with benign histopathology (negative results) to assess whether breast MRI follow-up is needed. MATERIALS AND METHODS. The medical records of patients who underwent 9-gauge breast MRI-guided VAB during 2007-2012 were reviewed retrospectively. Lesions with imaging-concordant benign histopathology results from MRI-guided VAB and surgery or 2 years or more of imaging follow-up were included. The false omission rate (1 - negative predictive value; [number of false-negative results / number of negative results]) of MRI-guided VAB was calculated. RESULTS. One hundred sixty-nine lesions were included, and 135 had only imaging follow- up (mammography follow-up: range, 17-107 months [median, 52 months]; MRI followup: range, 5-95 months [median, 35 months]). Of the 135 lesions with only imaging follow-up, 48 had mammography only (range, 26-86 months; median, 52 months), and 87 had mammography (range, 17-107 months; median, 52 months) and MRI (range, 5-95 months; median, 35 months). Thirty-four lesions had surgical correlation, and there were no cases of imaging-surgical discordance. Four malignancies were later diagnosed in the same breast in which MRIguided VAB had been performed. One (0.6%) malignancy was invasive ductal carcinoma at 1 cm from the MRI-guided VAB site; it was mammographically detected 24 months after MRIguided VAB. The other three malignancies developed 4 cm or more from the site of MRIguided VAB: one ductal carcinoma in situ (DCIS) detected on mammography 12 months after MRI-guided VAB, one DCIS detected on MRI 24 months after MRI-guided VAB, and one Paget disease lesion detected at physical examination 32 months after MRI-guided VAB. CONCLUSION. Breast MRI-guided VAB has a low false omission rate. MRI follow-up of lesions with concordant benign MRI-guided VAB histopathology results may not be warranted.

KW - Benign

KW - Breast

KW - Imaging-concordant

KW - MRI-guided

KW - Vacuum-assisted breast biopsy

UR - http://www.scopus.com/inward/record.url?scp=85016494063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016494063&partnerID=8YFLogxK

U2 - 10.2214/AJR.16.16576

DO - 10.2214/AJR.16.16576

M3 - Article

C2 - 28140609

AN - SCOPUS:85016494063

VL - 208

SP - 916

EP - 922

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 4

ER -